PPAR receptors and insulin sensitivity: New agonists in development;Récepteurs PPAR et insulinosensibilité: Nouveaux agonistes en développement

Annales d'Endocrinologie

Volumn 66, Issue 2 II, 2005, Pages

  Pegorier J P ^a  

^a INSTITUT COCHIN   (France)

Author keywords

Fatty acids; Insulin resistance; PPAR agonists; PPAR nuclear receptors; Rexinoids; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 METHYL 7 (5,6,7,8 TETRAHYDRO 5,5,8,8 TETRAMETHYL 3 PROPOXY 2 NAPHTHYL) 2,4,6 OCTATRIENOIC ACID; 5 (2,4 DIOXO 5 THIAZOLIDINYLMETHYL) 2 METHOXY N [4 (TRIFLUOROMETHYL)BENZYL]BENZAMIDE; 6 [1 (5,6,7,8 TETRAHYDRO 3,5,5,8,8 PENTAMETHYL 2 NAPHTHYL)CYCLOPROPYL]NICOTINIC ACID; BALAGLITAZONE; CLX 0921; DRF 2655; E 3030; EML 4156; FIBRIC ACID DERIVATIVE; FLUORENYLMETHOXYCARBONYLLEUCINE; GLIBENCLAMIDE; GLITAZONE DERIVATIVE; GW 0072; IMIGLITAZAR; LG 100641; LIGAND; LY 465608; LY 510818; LY 510929; MURAGLITAZAR; NAVEGLITAZAR; NNC 61 0645; PAT 5A; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ANTAGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PMT 13; RAGAGLITAZAR; RECEPTOR BLOCKING AGENT; REGLITAZAR; RETINOID X RECEPTOR; RETINOID X RECEPTOR AGONIST; REXINOID DERIVATIVE; ROSIGLITAZONE; T 0903131; TESAGLITAZAR; TY 51501; TZD 18; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DRUG CLASSIFICATION; FLUID RETENTION; GLUCOSE BLOOD LEVEL; HUMAN; IN VITRO STUDY; INSULIN SENSITIVITY; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PERIPHERAL EDEMA; REVIEW; SIDE EFFECT; WEIGHT GAIN;

ANIMALS; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; PPAR GAMMA;

EID: 17744365612     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. Picard F, Auwerx J. PPARγ and glucose homeostasis. Annu Rev Nutr 2002; 22: 167-97.
2. Host D, Grimaldi PA. New factors in the regulation of adipose differentiation and metabolism. Curr Opinion Lipid 2002; 13: 241-5.
3. Ferré P. The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes 2004; 53: S43-S50.
4. Larsen TM, Toubro S, Astrup A. PPARγ agonists: adipogenic treatment of type II diabetes. Int J Obes 2003; 27: 147-61.
5. Arner P. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol Metab 2003; 14: 137-45.
6. Stears AJ, Byrne CD. Adipocyte metabolism and the metabolic syndrome. Diabetes Obes Metab 2001; 3: 129-42.
7. Ferré P. Adiponectine: de l'adipocyte au muscle. Ann Endocrinol 2004; 65: 1S36-1S43.
8. Spiegelman BM. PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998; 47: 507-14.
9. Fajas L, Debril MB, Auwerx J. PPARγ: an essential role in metabolic control. Nutr Metab Cardiovasc Dis 2001; 11: 64-9.
10. Girard J. Mécanisme d'action des thiazolidinediones. Diabetes Metab 2001; 27: 271-8.
11. Mudaliar S, Henry RR. New oral therapies for type 2 diabetes mellitus: the glitazones or insulin-sensitizers. Annu Rev Med 2001; 52: 239-57.
12. Girard J. PPARγ et insulinorésistance. Ann Endocrinol 2002; 63: 1519-1522.
13. Lebovitz HE. Rationale for and role of thiazolidinediones in type 2 diabetes mellitus. Am J Cardiol 2002; 90 (suppl.): 34G-41G.
14. Blicklé JF. Place des thiazolidinediones dans le traitement du diabète de type 2. Presse Med 2004; 33: 1034-40.
15. Pégorier JP, Girard J. Thiazolidinediones et insulinosensibilité: rôle du récepteur nucléaire PPARγ. Ann Endocrinol 2004; 65: 65-72.
16. Gillies PS, Dunn CJ. Pioglitazone. Drugs 2000; 60: 333-43.
17. Belcher G, Matthews DR. Safety and tolerability of pioglitazone. Exp Clin Endocrinol Diabetes 2000; 108 (Suppl. 2): S267-S273.
18. Werner AL, Travaglini MT. A review, of rosiglitazone in type 2 diabetes mellitus. Pharmacotherapy 2001; 21: 1082-99.
19. Wagstaff AJ, Goa KL. Rosiglitazone: A review of its use in the management of type 2 diabetes mellitus. Drugs 2002; 62: 1805-37.
20. Monnier L, Sauvanet JP. Pioglitazone, insulinosensibilité et diabète de type 2: données récentes. Ann Endocrinol 2004; 65: 136-48.
21. Le Feuvre C. Effets cardio-vasculaires de la rosiglitazone. Presse Med 2004; 33: 735-45.
22. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998; 317: 703-13.
23. Plutzky J, Viberti G, Haffner S. Atherosclerosis in type 2 diabetes mellitus and insulin resistance: mechanistic links and therapeutic targets. J Diabetes Complic 2002; 16: 401-15.
24. Wulff EM, Pedersen KE, Sauerberg P. Balaglitazone, a new partial PPARγ agonist has a better cardiovascular safety profile and glycemic control compared with the full PPARγ agonist rosiglitazone. Diabetes 2003; 52 (suppl.1): A138-A139 [abstract 594-P].
25. Koev D, Ionescu-Trgoviste C, Rosenthal A, et al. Balaglitazone, a new thiazolidinedione, improves glucose and lipid control in patients with type 2 diabetes. Diabetes 2003; 52 (suppl.1): A124 [abstract 530-P].
26. Dey D, Medicherla S, Neogi P, et al. A novel peroxisome proliferator-activated gamma agonist, CLX-0921, has potent antihyperglycemic activity without adipogenic potential. Metabolism 2003; 52: 1012-8.
27. Chakrabarti R, Vikramadithyan RK, Kumar P, et al. PMT13, a pyrimidone analogue of thiazolidinedione improves insulin resistance-associated disorders in animal models of type 2 diabetes. Diabetes Obes Metab 2002; 4: 319-28.
28. Misra P, Chakrabarti R, Vikramadithyan RK, et al. PAT5A: a partial agonist of peroxisome proliferator-activated receptor gamma is a potent antidiabetic thiazolidinedione yet not adipogenic. J Pharmacol Exp Ther 2003; 306: 763-71.
29. Oberfield JL, Collins JL, Holmes CP, et al. A peroxisome proliferator-activated receptor-γ ligand inhibits adipocyte differentiation. Proc Natl Acad Sci USA 1999; 96: 6102-6.
30. Rocchi S, Picard F, Vamecq J, et al. A unique PPAR-γ ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol Cell 2001; 8: 737-47.
31. Berger JP, Petro AE, Macnaul KL, et al. Distinct properties and advantages of a novel peroxisome proliferator-activated protein-γ selective modulator. Mol Endocrinol 2003; 17: 662-76.
32. Kersey K, Floren LC, Pendleton B, Stempien MJ, Buchanan J, Dunn F. T0903131, a selective modulator of PPAR-gamma activity, increases adiponectin levels in healthy subjects. Diabetes 2004; 53 (suppl.2): A156 [abstract 656-P].
33. Pineda-Torra I, Chinetti G, Duval C, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice. Curr Opin Lipidol 2001; 12: 245-54.
34. Wang M, Tafuri S. Modulation of PPARgamma activity with pharmaceutical agents: treatment of insulin resistance and atherosclerosis. J Cell Biochem 2003; 89: 38-47.
35. Mukherjee R, Hoener PA, Jow L, et al. A selective PPARγ modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes. Mol Endocrinol 2000; 14: 1425-33.
36. Wright HM, Clish CB, Mikami T, et al. A synthetic antagonist for the peroxisome proliferator-activated receptor gamma inhibits adipocyte differentiation. J Biol Chem 2000; 275: 1873-7.
37. Yamauchi T, Waki H, Kamon J, et al. Inhibition of RXR and PPARγ ameliorates diet-induced obesity and type 2 diabetes. J Clin Invest 2001; 108: 1001-13.
38. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients. in patients with type 2 diabetes mellitus. JAMA 2000; 283: 1695-1702.
39. Freed MI, Ratner R, Marcovina SM, et al., for the Rosiglitazone Study 108 Investigators. Effects of rosiglitazone alone or in combination with atorvastatin on metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol 2002; 90: 947-52.
40. Vergès B. Antidiabétiques oraux et lipides. Ann Endocrinol 2002; 63: 1S45-1S50.
41. Lawrence JM, Reid J, Taylor GJ, Stirling C, Reckless JPD. Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes. Diabetes Care 2004; 27: 41-6.
42. Brunzell JD, Marconiva S, Yu D, et al. Rosiglitazone reduces novel biomarkers of cardiovascular disease in subjects with type 2 diabetes mellitus already on statin therapy. J Am Coll Cardiol 2004; 43 (Suppl.A): 236 [abstract 1124-192].
43. Smith U. Pioglitazone: mechanism of action. Int J Clin Pract 2001; Suppl.121: 13-18.
44. AFSSAPS. Traitement médicamenteux du diabète de type 2. Recommandations: texte long, argumentaire. Diabetes Metab 1999; 25(Suppl.6): 1-79.
45. Packard CJ. Overview of fenofibrate. Eur Heart J 1998; 19: A62-A65.
46. Keating GM, Ormrod D. Micronised fenofibrate. An updated review of its clinical efficacy in the management of dyslipidaemia. Drugs 2002; 62: 1909-44.
47. Chapman MJ. Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis 2003; 171: 1-13.
48. Vergés B. Clinical interest of PPARs ligands. Particular benefit in type 2 diabetes and metabolic syndromes. Diabetes Metab 2004; 30: 7-12.
49. Guerre-Millo M, Gervois P, Raspé E, et al. Peroxisome proliferator-activated receptor a activators improve insulin sensitivity and reduce adiposity. J Biol Chem 2000; 275: 16638-42.
50. Bajaj M, DeFronzo R, Suraamornkul S. Effects of PPAR-α/γ therapy on glucose/lipid metabolism, hepatic fat content, and plasma adiponectin concentration in patients with type 2 diabetes. Diabetologia 2004; 47 (suppl.1): A258 [abstract PS-714].
51. Seber S, Ucak S, Basat A, et al. The effects of dual PPARα/γ stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients. Diabetologia 2004; 47 (suppl.1): A258-A259 [abstract PS-715].
52. Wilson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs. From orphan receptors to drug discovery. J Med Chem 2000; 43: 527-50.
53. Chakrabarti R, Vikramadithyan RK, Misra P, et al. Ragaglitazar: a novel PPAR alpha-PPAR gamma agonist with lipid-lowering and insulin-sensitizing efficacy in animal models. Br J Pharmacol 2003; 140: 527-37.
54. Ljung B, Bamberg K, Dahllof B, et al. AZ 242, a novel PPARalpha/gamma agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats. J Lipid Res 2002; 43: 1855-63.
55. Hegarty BD, Furler SM, Oakes ND, Kraegen EW, Cooney GJ. Peroxisome proliferator-activated receptor (PPAR) activation induces tissue-specific effects on fatty acid uptake and metabolism in vivo. A study using the novel PPARα/γ agonist tesaglitazar. Endocrinology 2004; 145: 3158-64.
56. Harrity T, Chu C, Kunselman L, et al. Muraglitazar, a novel non-TZD dual PPARα/γ agonist, improves metabolic abnormalities in obese, severely diabetic db/db mice. Diabetes 2004; 53 (suppl.2): A31-A32 [abstract 134-OR].
57. Mosqueda-Garcia R, Frost CE, Swaminathan A, et al. Glucose lowering effects of multiple administration of muraglitazar (BMS-298585), a novel PPARα/γ dual agonist, in type 2 diabetic patients. Diabetes 2004; 53 (suppl 2): A32 [abstract 138-OR].
58. Murakami K, Tobe K, Ide T, et al. A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-α (PPARα) and PPARγ: effect of PPARα activation on abnormal lipid metabolism in liver of Zucker fatty rats. Diabetes 1998; 47: 1841-7.
59. Wagner J, Chun X, Rippley R, et al. Single and multiple doses of MK-0767 (KRP-297) reduce free fatty acids and lipids in healthy subjects. Diabetes 2003; 52 (suppl. 1): A137 [abstract 588-P].
60. Shibata T, Matsui K, Nagao K, Shinkai H, Yonemori F, Wakitani K. Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative. Eur J Pharmacol 1999; 364: 211-9.
61. Etgen GJ, Oldham BA, Johnson WT, et al. A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-α/γ agonist LY465608 ameliorates insulin resistance and diabetic hyperglycaemia while improving cardiovascular risk factors in preclinical models. Diabetes 2002; 51: 1083-7.
62. Etgen GJ, Broderick C, Oldham BA, et al. LY510929, a highly potent, non-TZD, PPARα/γ dual agonist for the treatment of type 2 diabetes and associated dyslipidemia. Diabetes 2003; 52 (suppl.1): A141 [abstract 605-P].
63. Prince M, Spicer K, Caro J, et al. Efficacy of LY519818, a novel non-TZD, PPAR γ-dominant α/γ dual agonist. Diabetes 2004; 53 (suppl 2): A33 [abstract 139-OR].
64. Guo Q, Sahoo SP, Wang PR, et al. A novel peroxisome proliferator- activated receptor α/γ dual agonist demonstrates favorable effects on lipid homeostasis. Endocrinology 2004; 145: 1640-8.
65. Inoue T, Yoshitomi H, Kasai S, et al. Hypoglycemic and hypolipidemic effects of a novel dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, E3030, in db/db mice. Diabetes 2004; 53 (suppl.2): A129 [abstract 544-P].
66. Kasai S, Inoue T, Yoshitomi H, et al. Hypolipidemic effects of a novel dual PPARα/γ agonist, E3030, in beagle dogs. Diabetes 2004; 53 (suppl.2): A131 [abstract 553-P].
67. Vikramadithyan RK, Hiriyan J, Suresh J, et al. DRF 2655: a unique molecule that reduces body weight and ameliorates metabolic abnormalities. Obes Res 2003; 11: 292-303.
68. Chevreuil O, Contard F, Guerrier D. LM 4156, a novel, balanced activator of PPAR α and γ improves dyslipidemia in fa/fa Zucker rats. Diabetes 2003; 52 (suppl.1): A114 [abstract 488-P].
69. Contard F, Berard I, Yvon S, Decerprit J, Guerrier D. LM 4156, a novel, balanced activator of PPAR α and ψ with anti-hyperglycemic and HDL elevator properties in db/db and human apoA1 mice. Diabetes 2003; 52 (suppl.1): A115 [abstract 492-P].
70. Satoh H, Kubota N, Terauchi Y, et al. TY-51501, a novel halobenzyltyrosine derivatives, ameliorates insulin resistance and up-regulates adiponectin in vivo. Diabetes 2003; 52 (suppl.1): A144 [abstract 616-P].
71. Brand CL, Sturis J, Gotfredsen CF, et al. Dual PPARalpha/ gamma activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats. Am J Physiol Endocrinol Metab 2003; 284: E-841-54.
72. Gregg RE, Swaminathan A, Frost C, Nepal S, Raymond R, Mosqueda-Garcia R. Muraglitazar, a novel PPAR alpha/ gamma dual agonist, lowers fasting plasma glucose, triglycerides, non esterified fatty acids and apolipoprotein (APO) CIII after once a day administration in type 2 diabetic patients. Diabetologia 2004; 47 (suppl. 1): A259 [abstract PS-717].
73. Saad MF, Greco S, Osei K, et al. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects. Diabetes Care 2004; 27: 1324-9.
74. Ye JM, Iglesias MA, Watson DG, et al. PPARalpha/gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly. Am J Physiol Endocrinol Metab 2003; 284: E-531-40.
75. Vidal H. Données nouvelles sur les récepteurs PPAR. Ann Endocrinol 2005; 66: 1S5-1S9.
76. Grimaldi PA. Roles of PPARdelta in the control of muscle development and metabolism. Biochem Soc Trans 2003; 31: 1130-2.
77. Lewis MC, Wilson JG, Ignar DM, Oliver WR Jr. The effects of PPARα, δ and PPARpan™ agonists on diet-induced obesity in fat-fed AKR mice. Diabetes 2004; 53 (suppl. 2): A134 [abstract 565-P].
78. Ortmeyer HK, Collins CA, Minnick DT, et al. PPARpan™ agonist treatment improves lipid utilization via tissue-specific effects on skeletal muscle and adipose tissue lipoprotein lipase activity in obese monkeys. Diabetes 2004; 53 (suppl. 2): A159 [abstract 666-P].
79. Mukherjee R, Davies PJA, Crombie DL, et al. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 1997; 386: 407-10.
80. Forman BM. The antidiabetic agent LG100754 sensitizes cells to low concentrations of peroxisome proliferator-activated receptor gamma ligands. J Biol Chem 2002; 277: 12503-6.
81. Cesario RM, Klausing K, Razzaghi H, et al. The rexinoid LG100754 is a novel RXR: PPARgamma agonist which decreases glucose level in vivo. Mol Endocrinol 2001; 15: 1360-9.